Diabetes research and clinical practice · 2026
Continuous glucose monitoring for cystic fibrosis-related diabetes: impact on quality of life and glycaemic control.
СтатьяКлиническое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martini Renee, Samm De-Arne, Routley Ashlee, Gagliardi Lucia, Chapman Sally, Hopkins Emily, Umapathysivam Mahesh, Morton Judith
Аннотация
BACKGROUND/AIMS: Data for the use of continuous glucose monitoring (CGM) in cystic fibrosis related diabetes (CFRD) is lacking. The aim of this study is to establish efficacy and safety of CGM in CFRD to improve glycemic control and quality of life.
METHODS: A prospective single-arm trial of 3 months CGM (Libre2®) in insulin requiring CFRD. All outcomes were assessed at baseline, completion of intervention and 3 months post completion. Glycemic control was assessed by glycated haemoglobin (HbA1c) and CGM metrics. QOL assessed by Problem Areas in Diabetes (PAID).
RESULTS: 19 subjects were recruited. Median baseline HbA1c was 8.7% (72 mmol/mol) (IQR:8-10.6%, 64-92 mmol/mol), decreasing to 7.8% (62 mmol/mol) (IQR:7.3-8.3%, 56-67 mmol/mol), (p = 0.018) at completion of intervention, and remained lower than baseline at 8.0% (64 mmol/mol) (IQR: 7.0-9.0%, 53-75 mmol/mol) at 3 months post study intervention. Median baseline PAID score was 29.0 (IQR:16.0-48.5), decreasing to 16.0 (IQR: 11.0-22.0) (p = 0.02) at completion of intervention. At 3 months post completion median increased to 19.0 (IQR 11.5-23.0). There was no increase in time spent <3.0 mmol/L before and after sensor use (0.0% vs 0.3% p = 0.50).
CONCLUSION: CGM use in CFRD improved QOL and glycaemic control without increases in hypoglycaemia.
METHODS: A prospective single-arm trial of 3 months CGM (Libre2®) in insulin requiring CFRD. All outcomes were assessed at baseline, completion of intervention and 3 months post completion. Glycemic control was assessed by glycated haemoglobin (HbA1c) and CGM metrics. QOL assessed by Problem Areas in Diabetes (PAID).
RESULTS: 19 subjects were recruited. Median baseline HbA1c was 8.7% (72 mmol/mol) (IQR:8-10.6%, 64-92 mmol/mol), decreasing to 7.8% (62 mmol/mol) (IQR:7.3-8.3%, 56-67 mmol/mol), (p = 0.018) at completion of intervention, and remained lower than baseline at 8.0% (64 mmol/mol) (IQR: 7.0-9.0%, 53-75 mmol/mol) at 3 months post study intervention. Median baseline PAID score was 29.0 (IQR:16.0-48.5), decreasing to 16.0 (IQR: 11.0-22.0) (p = 0.02) at completion of intervention. At 3 months post completion median increased to 19.0 (IQR 11.5-23.0). There was no increase in time spent <3.0 mmol/L before and after sensor use (0.0% vs 0.3% p = 0.50).
CONCLUSION: CGM use in CFRD improved QOL and glycaemic control without increases in hypoglycaemia.